Gossamer Bio appoints CEO Greg Ciongoli to board
Gossamer Bio appointed longtime biopharma investor Greg Ciongoli to its board to support the advancement of its pipeline, including the PAH therapy seralutinib.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed